Collagen peptide-based medicament compositions and devices and methods of production and use thereof
The present invention is in the fields of medicinal chemistry, biotechnology and pharmaceuticals. The invention provides compositions comprising one or more collagen mimetic peptides, optionally attached to one or more therapeutic compounds or one or more imaging compounds, for use in methods of treating, preventing, ameliorating, curing and diagnosing certain diseases and physical disorders in humans and veterinary animals, particularly anterior and posterior segment ocular diseases and physical disorders, paraocular and extraocular diseases and physical disorders, and nerve or nervous system diseases and physical disorders, as well as methods of manufacturing such compositions. The invention also provides medical devices comprising one or more such compositions of the invention. The invention also provides methods of use of such compositions and devices in treating and diagnosing certain diseases and physical disorders in humans and veterinary animals, including anterior and posterior segment ocular diseases or disorders, paraocular and extraocular diseases and physical disorders, and nerve or nervous system diseases or disorders.
1. A method of treating a posterior segment disease, disorder or wound, a paraocular disease, disorder or medical condition, an extraocular disease, disorder or medical condition, or an anterior segment ocular disease, disorder or wound, in a human or veterinary animal suffering from or predisposed to said ocular disease, disorder or wound, comprising administering a composition comprising (a) at least one collagen mimetic peptide (CMP) comprising the amino acid sequence of SEQ ID NO: 6, and (b) one or more pharmaceutically suitable carriers to an eye of said human or veterinary animal in a dosage sufficient to treat said posterior segment ocular disease, disorder or wound, monitoring the condition of the eye in said human or veterinary animal over time, and readministering said composition to the eye until said posterior segment ocular disease, disorder or wound is treated or ameliorated.
2. The method of claim 1 , wherein said posterior segment ocular disease, disorder or wound involves the retina, retinal blood vessels, retinal nerves or optic nerve.
3. The method of claim 2 , wherein said posterior segment ocular disease or disorder involves the retinal epithelium.
4. The method of claim 2 , wherein said posterior segment ocular disease or disorder is selected from the group consisting of macular degeneration, retinitis pigmentosa, a retinal tear, retinal detachment, retinopathy, retinal arterial or venous occlusion, optic neuritis, optic neuropathy and optic atrophy.
5. The method of claim 4 , wherein said macular degeneration is selected from wet macular degeneration, dry macular degeneration and age-related macular degeneration.
6. The method of claim 4 , wherein said retinopathy is diabetic retinopathy.
7. The method of claim 1 , wherein said composition is administered to the eye conjunctivally or subconjunctivally.
8. The method of claim 7 , wherein said subconjunctival administration is achieved by administering said composition into the subconjunctival fornix.
9. The method of claim 1 , wherein said composition is administered to the eye in the form of one or more drops of solution or a suspension that contains the composition.
10. The method of claim 1 , wherein said composition is administered to the eye via injection.
11. The method of claim 1 , wherein said composition is administered to the eye in the form of a coating on a solid material that is implanted into an eye structure.
12. The method of claim 1 , wherein said composition is administered to the eye in the form of a wafer, film, gel, mesh or patch.
13. The method of claim 1 , wherein said composition is attached to one or more spheres or nanoparticles that are delivered to or into an eye structure.